drugset / Trial / NCT07410039
Therapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World Study
RandomizedParallel-groupOpen-labelTreatment
Summary
This project is a multi-center, prospective, real-world cohort study that collects clinical data of Chinese patients with AQP4-positive NMOSD in the acute stage. It comprehensively assesses the clinical outcomes of the patients and aims to compare the clinical efficacy and safety of icoxib as a combined add-on treatment versus simple hormone shock therapy during the acute phase of NMOSD.Using simple hormone shock therapy (IVMP) as the control group, the efficacy and safety of etanercept treatment in the acute attack phase of Chinese patients with AQP4-positive neuromyelitis optica spectrum disorder (NMOSD) were evaluated.
Timeline
- Start
- 2026-02-01
- Primary completion
- 2027-06-30
- Completion
- 2029-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Eculizumab | Monoclonal antibody | 900 mg | Intravenous |
| Comparator | Human immunoglobulin | Protein / enzyme biologic | 0.4 g/kg | Intravenous |
| Comparator | Methylprednisolone | Other / unclassified | 120 mg | Intravenous |